Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms

Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms

Zebrafish has proven to be a versatile and reliable experimental in vivo tool to study human hematopoiesis and model hematological malignancies. Transgenic technologies enable the generation of specific leukemia types by the expression of human oncogenes under specific promoters. Using this technolo...

Full description

Bibliographic Details
Main Authors:	Daniela Zizioli, Simona Bernardi, Marco Varinelli, Mirko Farina, Luca Mignani, Katia Bosio, Dario Finazzi, Eugenio Monti, Nicola Polverelli, Michele Malagola, Elisa Borsani, Giuseppe Borsani, Domenico Russo
Format:	Article
Language:	English
Published:	MDPI AG 2021-02-01
Series:	Cells
Subjects:	zebrafish chronic myeloid leukemia (CML) BCR-ABL1 transgenic animal model UAS/hsp70-Gal4 embryonic development
Online Access:	https://www.mdpi.com/2073-4409/10/2/445

Similar Items

Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
by: Erin Clapper, et al.
Published: (2020-03-01)

Evaluation of 5‐year imatinib treatment of 458 patients with CP‐CML in routine clinical practice and prognostic impact of different BCR‐ABL cutoff levels
by: Hana Klamová, et al.
Published: (2013-04-01)

A study to determine the clinical, hematological, cytogenetic, and molecular profile in CML patient in and around Eastern UP, India
by: Sandip Kumar, et al.
Published: (2019-01-01)

Molecular diagnosis of bcr-abl fusion gene in CML patients using Monoplex-Two Steps- Reveres Transcriptase–Polymerase Chain
by: Maysaa A. Dhahii
Published: (2010-04-01)

The study of the impact of additional chromosomal aberrations and c-MYC and BCR::ABL1 genes amplification on CML patient’s characteristics: relation to haematological parameters and patient outcome
by: Hend Attia, et al.
Published: (2023-12-01)

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
by: Anna Kreutzman, et al.
Published: (2019-09-01)

PEG-Bottlebrush Stabilizer-Based Worm-like Nanocrystal Micelles with Long-Circulating and Controlled Release for Delivery of a BCR-ABL Inhibitor against Chronic Myeloid Leukemia (CML)
by: Huamin Liang, et al.
Published: (2022-08-01)

Frequency of BCR-ABL Fusion Transcript in Iranian Patients with Chronic Myeloid Leukemia
by: M Yaghmaie, et al.
Published: (2005-09-01)

Frequency of BCR-ABL Fusion Transcript in Iranian Patients with Chronic Myeloid Leukemia
by: Yaghmaie M., et al.
Published: (2005-09-01)

Molecular Pathogenesis and Treatment Strategies of Chronic Myeloid Leukemia (CML)
by: Rabia Khalid, et al.
Published: (2023-12-01)

Complete Molecular Response due to nilotinib as III line treatment in a patient with CML and F317L point mutation of the Bcr-Abl kinase domain
by: Maria Iovine, et al.
Published: (2015-10-01)

Quantification of Main Bcr-abl Gene Transcripts in CML Patients Using Competitive RT-PCR
by: Ali Nazemi, et al.
Published: (2016-04-01)

Baseline blood count levels increase odds of cytopenia among CML patients in Kenya: a case control study
by: Angela McLigeyo, et al.
Published: (2022-02-01)

Detection of p190BCR-ABL AND p210BCR-ABL fusion transcripts in patients with chronic myeloid leukemia (CML) using qualitative RT-PCR
by: Aya Bonilla, Carlos Alberto, et al.
Published: (2014-10-01)

Quantification of main bcr-abl gene transcripts in CML patients using competitive RT-PCR
by: Ali Nazemi, et al.
Published: (2016-04-01)

Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients
by: Mahmood S. Khazaal, et al.
Published: (2019-08-01)

In Silico Molecular Modeling of Four New Afatinib Derived Molecules Targeting the Inhibition of the Mutated Form of BCR-ABL T315I
by: Kelvyn M. L. Rocha, et al.
Published: (2024-09-01)

Unveiling the nephrotoxic profile of BCR‐ABL tyrosine kinase inhibitors: A real‐world experience in Africa
by: Zekarias Seifu Ayalew, et al.
Published: (2024-08-01)

Chronic Myeloid Leukaemia with isolated massive thrombocytosis and BCR‐ABL1 detection failure using RT‐MLPA (positive RT‐qPCR)
by: Lucie Coster, et al.
Published: (2021-08-01)

Fusion gene bcr-abl: From etiopathogenesis to the management of chronic myeloid leukemia
by: Tri Agusti Sholikah
Published: (2017-04-01)

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
by: Maria Stella Pennisi, et al.
Published: (2019-08-01)

Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients
by: Lenka Hovorkova, et al.
Published: (2024-07-01)

The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach
by: Ting-Ting Huang, et al.
Published: (2021-03-01)

Detection of derivative 9 deletion by BCR-ABL fluorescence in-situ hybridization signal pattern to evaluate treatment response in CML patients
by: Bakshi Sonal R., et al.
Published: (2009-01-01)

NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE
by: Gianfranco Catalano, et al.
Published: (2020-10-01)

The molecular mechanisms underlying BCR/ABL degradation in chronic myeloid leukemia cells promoted by Beclin1-mediated autophagy
by: Huang X, et al.
Published: (2019-06-01)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
by: Dachuan Zeng, et al.
Published: (2022-05-01)

Emergence role of nucleated red blood cells in molecular response evaluation for chronic myeloid leukemia
by: Phan TT, et al.
Published: (2019-09-01)

Transcripto BCR-ABL atípico en un paciente con leucemia mieloide crónica Atypical BCR-ABL transcript in a patient with chronic myeloid leukemia
by: Ana María Amor Vigil, et al.
Published: (2011-09-01)

Higher prevalence of harbouring BCR::ABL1 in first-degree relatives of chronic myeloid leukaemia (CML) patients compared to normal population
by: Jew Win Kuan, et al.
Published: (2024-06-01)

BCR-ABL kinase domain mutations in CML patients, experience from a tertiary care center in North India
by: Akhilesh S, et al.
Published: (2024-01-01)

A novel BCR-ABL1 fusion gene with genetic heterogeneity indicates a good prognosis in a chronic myeloid leukemia case
by: Fen Zhou, et al.
Published: (2017-05-01)

Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts
by: Michele Massimino, et al.
Published: (2021-06-01)

Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
by: Michele Massimino, et al.
Published: (2018-02-01)

<i>Sphagneticola Trilobata</i> (L.) Pruski (Asteraceae) Methanol Extract Induces Apoptosis in Leukemia Cells through Suppression of BCR/ABL
by: Hoang Thanh Chi, et al.
Published: (2021-05-01)

BCR-JAK2 fusion as a result of a translocation (9;22)(p24;q11.2) in a patient with CML-like myeloproliferative disease
by: Elnaggar Mohamed M, et al.
Published: (2012-05-01)

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
by: Diletta Fontana, et al.
Published: (2021-11-01)

Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias
by: Stephanie M. Smith, et al.
Published: (2021-04-01)

Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1
by: Hao Zhang, et al.
Published: (2022-03-01)

Small Molecules as Potential Inhibitors of the 14-3-3/c-Abl Interaction for the Treatment of CML
by: Leire Iralde-Lorente, et al.
Published: (2019-08-01)